Page 1 of 24
Browse Innovations
i). Our patented AI-SaMD: iOsteoporos Screen is the stand-alone, AI-powered software tool automatically analysing routine chest X-rays to predict osteoporotic fracture risk in post-menopausal women and geriatric individuals. Within 1-2 minutes, it generates automated AI Insight Reports accessible via both desktop computer and cloud-based platforms including mobile app and SaaS. It is primarily supported by BIRAC, Government of India. It's TRL is 5- 6, Class-B type. Its clinical validation in hospital is in progress; Pilot testing was completed in two hospitals and is underway in two more.
ii). This innovation addresses India's critical gap where less than one DXA machine per 100K people. Using advanced AI with ensemble deep learning-machine learning combined with with automated clavicle radiogrammetry, it evaluates thoracic skeletal features and clavicle cortical bone indices to predict DXA-independent hip and spine bone density markers, classifying osteoporosis risk and fracture probability.
iii). CDSCO’s test-licensed by Government of India, the solution achieved 97% sensitivity validated across two hospitals against DXA T-scores as standards, adhering to WHO and ICMR guidelines. IP-protected with US national phase entry, it requires only cost-effective routine chest X-rays, no additional equipment or infrastructure needed. Designed for ease of use, health workers, nurses, or trained computer operators can operate it without specialized training. Ready for PACS/EHR and ABDM integration
vi). Video Links:
a). Product Demo: iOsteoporos Screen- Mobile App (https://youtube.com/shorts/EKIhJ4QEaJA)
b). Product Demo: iOsteoporos Screen- SaaS (https://youtu.be/xeoGzkPXpJw)
c). About our innovation: iOsteoporos Screen (https://youtu.be/SRNPz9na3-Q)
Here, we focus on developing drugs that induce a conformational change in the InhA enzyme by utilizing slow-onset inhibitors through Artificial Intelligence-driven approaches
This innovation introduces a novel enzyme-based approach to address the global challenge of drug-resistant Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). The solution encompasses both therapeutic and diagnostic applications, leveraging a unique enzyme formulation that directly targets the robust mycolic acid-containing cell wall of Mtb. By destabilizing this critical barrier, the enzyme facilitates both enhanced drug delivery for treatment and simplified sample preparation for diagnostics, offering a potential breakthrough in combating multi-drug-resistant (MDR) and extensively drug-resistant (XDR) TB strains.
The enzyme-based therapy focuses on the direct degradation of the Mtb cell wall, specifically targeting the mycolic acid-containing outer membrane. This membrane, a hallmark of Mycobacterium species, provides a formidable barrier that contributes to the bacterium’s resistance to conventional antibiotics. The enzyme destabilizes this structure by enzymatically removing outer membrane-embedded porins, which are essential for nutrient uptake and bacterial survival. This disruption compromises the integrity of the cell wall, leading to bacterial lysis or increased susceptibility to other drugs.
When used in combination with existing TB drugs, the enzyme enhances drug diffusion into the bacterial cell by weakening the cell wall, allowing approved antibiotics to more effectively target intracellular components. This synergistic approach not only restricts bacterial proliferation but also limits further infection, offering a promising strategy to control drug-resistant TB.
The enzyme-based therapy stands out from existing TB treatments in several critical ways:
The therapeutic development plan includes:
Current TB diagnostics, particularly sputum-based molecular tests, face significant barriers, including the inability of some patients to produce sputum and the reliance on equipment-intensive mechanical lysis methods. These limitations restrict access to diagnostics in resource-limited settings. The enzyme-based approach offers a transformative solution by enabling sputum-free diagnostics through the use of tongue swabs and simplifying sample preparation.
The enzyme disrupts the Mtb cell wall to release intracellular components, such as DNA, for diagnostic detection. This eliminates the need for complex mechanical lysis, reducing assay complexity and cost. The enzyme’s ability to destabilize the mycolic acid membrane ensures efficient sample preparation, making it compatible with molecular diagnostic techniques like PCR.
The diagnostic development plan includes:
The enzyme has been successfully tested on Mycobacterium smegmatis, a non-pathogenic model organism for Mtb, demonstrating effective cell wall disruption via spot diffusion assays. Additionally, specificity tests on E. coli strains (including K12 and expression strains) and human cell lines (A549, HEK, and CHO) showed no toxicity, indicating a favorable safety profile for both therapeutic and diagnostic applications.
The innovation targets two critical markets:
This enzyme-based innovation represents a dual-purpose breakthrough in TB management, addressing both treatment and diagnostic challenges posed by drug-resistant Mycobacterium tuberculosis. By directly targeting the mycolic acid cell wall, the enzyme offers a novel mechanism to overcome resistance, enhance drug efficacy, and simplify diagnostics. With promising preliminary results and a clear development roadmap, this solution has the potential to transform TB care, particularly for vulnerable populations and in resource-limited settings.
TB is an infectious airborne disease, whose main etiologic agent is MTb. Although TB is present in every country in the world, this disease mainly affects low-income and vulnerable populations. TB is among the 10 leading causes of death in the world, and the first as an infectious agent in HIV Positive patients. In 2019, TB was responsible for over 1 million deaths. WHO estimates that one-fourth of the world's population is infected with MTb.
Presently existing LAM urine test (Alere, Abbott, USA) has higher sensitivity & specificity, mainly in HIV co-infected TB patients, while its sensitivity and specificity are very less in active TB patients 17-40% average 26 percentage. We propose an improved version of a visual, qualitative, rapid, and affordable test (LAM-Based TB test) for mass screening of TB in urine. Tests are rapid, and results can be interpreted in 10 minutes. The proposed tests are suitable for doctors’ clinics and resource-constrained areas, and no refrigeration is required during storage and transportation. Lipoarabinomannan (LAM) is a potential marker of active tuberculosis (TB). The test is based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in body fluids (blood and sputum etc) that can be used as a potential point of care test for tuberculosis (TB). LAM antigen is a lipopolysaccharide present in mycobacterial cell walls, which is released from metabolically active or degenerating bacterial cells and appears to be present only in people with active TB disease.
Urine-based testing would have advantages over sputum-based testing because urine is easy to collect and store, and lacks the infection control risks associated with sputum collection. This rapid Test is a membrane-based test for the rapid detection of cell wall antigen in urine. Our proposed TB test (detection of antigen in Urine) is rapid (20-25 minutes compared to 8 to 12 weeks for routine culture), low cost and affordable (compared to USD20 for Gene Xpert), do not require equipment, they are point of care easy to use tests and only small amount of sample is needed for the test. The tests can be performed in rural and resource settings where pathology labs or TB labs are not available.
We have completed clinical validation of Rapid Tests in urine samples of TB and HIV co-infected TB patients at one site (Fiocruz, Recife, Brazil) under the BRICS Project. As a result, we found higher accuracy than Alere LAM (Abbott) and FujiLAM (Japan) TB tests. Further, investigations and validation studies are going on in Fiocruz, Rio De Janeiro, Brazil to increase its accuracy and make it suitable for mass screening of TB in adult as well as pediatric TB populations in rural and resource-constrained areas of India, China, Brazil, and South Africa (High Burden Countries).
This system combines five essential respiratory care and diagnostic functions into a modular, compact, and interchangeable platform, enabling clinicians (especially suited for primary care and high-burden settings) to rapidly adapt to diverse patient needs with minimal equipment changeover. A multifunctional, high-flow, oxygen-compatible aerosol control device designed for integrated respiratory support and efficient sputum collection to be deployed at a health facility.
truGnom is a next-generation, formalin- and alcohol-free genetic material preservation solution developed by Ruhvenile for any biological sample collection, transportation, and preservation for molecular analysis (PCR, RT-PCR, NGS, WGS, OMICs)
Key Features
Applications
Target Users:
Advantages Over Traditional Media
truGnom | Traditional Media |
Room temperature transport (48 hrs) | Requires cold chain |
No additional lysis steps | Multiple processing steps |
2.5-3X higher yields | Standard yields |
Formalin & alcohol-free | May contain hazardous chemicals |
Color indicator for integrity | No visual quality check |
Available Formats
250 mL | 500 mL | 1.0 L | Bulk quantities
Current users: Clinical sample Users: PGIMER, Chandigarh | AIIMS, Delhi | SKIMS, Srinagar | AIIMS, Bhopal | KEM Mumbai | MNC Chennai | IPGMER Kolkata | SGPGI Lucknow | SMS Jaipur | RIMS Manipur | Medical college, Thiruvananthapuram | NCL Pune & more Institutes…
Immunocompetent host limit the mycobacterial infection in granulomatic lesions which is an indicative of host immunity against infection. Several studies including ours have demonstrated the active involvement of Sphingolipids on host innate response against M .tuberculosis (Sharma et al, 2017). Of particular note our pioneer and compelling study has advocated that Sphingosine -1 phosphate; the key Sphingolipid moiety is capable of controlling M. tb infection (Nadella et al, 2020) and unpublished data. As S1P is potentially allergic in nature therefore this may not qualify the criteria of new anti-tubercular agent.
In view of this, our unpublished data have shown antimycobacterial potential of ATLS-PA2021 in variety of model we tested including animal challenge. More importantly L serine enhanced the sensitivity of both wild type and MDR strain of mycobacteria for Rifampicin and 2nd line Anti tubercular drugs which indicated adjunct potential of ATLS-PA2021 which we have patented in past. On the basis of these results, we plan to develop ATLSPA based adjunct for 1st and 2nd line Anti tubercular drugs for improving their sensitivity and effective killing of MDR TB.
Based on our striking data, we propose that these combinations, apart from clearing infection, would also tweak polarization of macrophages and T cell to their effector phenotype. We believe that such Sphingolipids directed therapeutics would also reprogram foamy macrophages and contribute significantly in managing MDR Tuberculosis burden in host.
For the first time, the Community Radio-Led TB Awareness and Behavior Change Model (CR-TB ABC), developed by SMART, places Jan Bhagidari at the core of TB elimination efforts. This model transforms Community Radio from a passive information channel into an active catalyst for behavior change. CR-TB ABC fosters co-creation by integrating local knowledge, survivor voices, and government interventions into a participatory framework that drives early detection, stigma reduction, treatment adherence, and community-led support for TB patients.
Key components of the model include:
Timely and accurate diagnosis of bacterial drug resistance is crucial to preventing severe patient outcomes. Given the risks of resistance, early detection is essential not only for effective treatment but also to minimize recurrence and aid in disease control. Globally, diagnosing drug-resistant tuberculosis is a top priority to mitigate its long-term impact. Currently, the most reliable method relies on liquid media, delivering results in about 14 days. However, these tests are costly and require specialized laboratory facilities with strict biosafety measures.We optimize a paper-based microfluidic platform for the detection of M. tuberculosis.
Our methodology involves drug susceptibility testing with the culture filtrate and LRP assay protocol. We exploit the paper-based platforms for the testing of ~ 50 cultures of M. tuberculosis isolates. The key advantage of the developed platforms is fast, easy and inexpensive detection; it provides the results within ~ 3 hours, while the consumption of the necessary reagents is ~50 micro-liters. Mycobacteriophages are the class of viruses known to specifically infect mycobacteria. Techniques involving mycobacteriophages have been developed and evaluated for primary detection and thereafter for drug susceptibility testing.
Currently available techniques involve performing drug susceptibility testing from the primary cultures which requires a minimum of 7 to 28 days based on the associated protocols. The fastest approach even takes ~7 days, requires very expensive reagents and sophisticated infrastructures. From recent literature, a microfluidics-based approach seems to be an effective tool to resolve the aforesaid concerns. Here, we propose a procedure which is very economical and will be able to diagnose rifampicin and isoniazid susceptibility as early as within ~3 hours.
